OBJECTIVES: Uncontrolled moderate to severe asthma is difficult to treat with standard treatments and new therapies for this indication are increasingly expensive. Personalized medicine (PM) could allow an efficient use of targeted therapies and a better control of the disease. This study aims to develop a global economic model to assess the economic impact of PM testing for the treatment of uncontrolled moderate to severe asthma. METHODS: Two literature reviews were conducted to retrieve economic evaluations (1) on moderate to severe asthma treatment and (2) on PM in asthma to identify key parameters for the development of the decision tree. The economic impact of PM testing to guide the choice of treatment for uncontrolled moderate to severe asthma can be assessed from a provincial Ministry of Health (MoH) or a societal perspective over a 1-year period. Asthma exacerbations were the main efficacy parameter considered and costs included were treatments, resource utilization, administration, follow-up and productivity loss. Values were extracted from literature and governmental publications. The model was tested in an applied context, using the blood type-E immunoglobulin (IgE) assay to guide treatment with omalizumab compared with no testing (omalizumab for all). RESULTS: When tested, total cost reduction was -$8,811 and -$9,225 from a MoH and a societal perspective respectively for a total QALY gain of 0.06 per patient, which lead to a dominant strategy for IgE testing compared to no testing. According to deterministic analysis results, IgE testing remains a dominant strategy over no testing in all scenarios tested. However, parameters with the greatest impact on base-case ICURs were the prevalence of allergic asthma and the cost of omalizumab. CONCLUSIONS: The global economic model can help estimating on a similar basis the economic impact of several technologies using PM testing to guide the treatment of uncontrolled moderate to severe asthma.